ARKG News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AR

Volume

9.79M

Loading chart

AR

ARKGARK Genomic Revolution ETF

ARKG

Pay with—

Available Balance0.00

AR

AUM

N/A

Volume

9.79M

Yield

0.82%

Chart Earnings News About Insider Filings

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtCathie Wood's Ark Invest added to positions in Nvidia, Broadcom, and Intellia Therapeutics on Friday as these stocks declined. Nvidia exceeded earnings expectations with 106% revenue growth and raised guidance to 70% for fiscal 2028, now trading at 14x forward earnings. Broadcom is on track for accelerating growth with an upcoming earnings report. Intellia, a gene-editing biotech, has declined over 50% from recent highs but remains well-funded with analyst support.The Motley Fool · Aug 31, 2026

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingCathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.The Motley Fool · Jul 22, 2026

Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?Cathie Wood's Ark ETFs sold over $11 million worth of Twist Bioscience stock on June 30, 2026, despite the synthetic DNA manufacturer's stock climbing 190% year-to-date. The sales appear to be portfolio rebalancing rather than a loss of confidence, as Ark still holds over $332 million in Twist across its ETFs. The proceeds were used to purchase stakes in other companies like Circle Internet Group and SoFi Technologies.The Motley Fool · Jul 19, 2026

Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score DropsCRISPR Therapeutics AG, a major holding in Cathie Wood's ARK funds, faces significant headwinds as its momentum score plummeted from 76.81 to 50.97 following a 10% stock decline. The decline was triggered by CEO insider share sales exceeding 90,000 shares and disappointing Q3 revenue of just $890,000, far below the $8.06 million consensus estimate, signaling weak product adoption.Benzinga · Jan 27, 2026

FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal CancerThe FDA approved Guardant Health's Guardant360 CDx blood test as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Pfizer's Braftovi treatment combined with cetuximab and chemotherapy. This marks the 25th companion diagnostic indication for the platform and expands non-invasive genomic testing access. Guardant Health stock surged 2.27% to $118.37, trading at a 52-week high with strong technical momentum.Benzinga · Jan 22, 2026

Why Tempus AI Stock Soared This WeekTempus AI stock rose 10.9% this week after Ark Invest ETFs added shares to their portfolios and a BTIG analyst raised the price target to $105, indicating potential growth in AI healthcare technology.The Motley Fool · Nov 28, 2025

Net Asset Value(s)This article provides the daily fund prices for various WisdomTree ETFs as of March 26, 2025. It covers a wide range of ETFs, including those focused on artificial intelligence, bonds, commodities, equities, and emerging markets.GlobeNewswire Inc. · Mar 27, 2025

Here Are the 6 Largest Stock Holdings in All of Cathie Wood's ETFs Right NowCathie Wood's Ark Invest offers several actively managed ETFs focused on different tech-related sectors. While her funds have had strong performance, they have been light on AI-focused investments. This article provides an overview of Ark's largest ETFs and their top holdings.The Motley Fool · Jan 22, 2025

Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.Ark Funds, managed by Cathie Wood, have underperformed the broader market in recent years due to their focus on volatile technology sectors that require a specific economic environment to thrive. The funds' high turnover and concentration risks have also contributed to their underperformance.The Motley Fool · Aug 27, 2024

Why Ginkgo Bioworks Stock Is Sinking TodayThere was double trouble for this beaten-down biotech stock.The Motley Fool · Jun 26, 2024

to start trading

AR

ARKGARK Genomic Revolution ETF

ARKG

Pay with—

Available Balance0.00

Your PositionYou don't own any ARKG yet.

Related Tickers

Earnings